Corticosteroids in chronic inflammatory demyelinating polyneuropathy

Autor: Francesca Gallia, Camiel Verhamme, Ivana Basta, I. N. van Schaik, Eduardo Nobile-Orazio, Pietro Emiliano Doneddu, Stojan Peric, Ana Nikolic, Luuk Wieske, Filip Eftimov, G. G. A. van Lieverloo
Přispěvatelé: Neurology, ANS - Neuroinfection & -inflammation, AII - Inflammatory diseases
Rok vydání: 2018
Předmět:
Zdroj: Journal of neurology, 265(9), 2052-2059. D. Steinkopff-Verlag
ISSN: 1432-1459
0340-5354
DOI: 10.1007/s00415-018-8948-y
Popis: Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) can be treated with corticosteroids or intravenous immunoglobulins. Various corticosteroid regimens are currently used in CIDP, but it is unknown whether they are equally efficacious. In this retrospective study, we compared efficacy and safety of three corticosteroid regimens in CIDP patients. Methods: We included treatment naïve patients that fulfilled the EFNS/PNS criteria for CIDP. Patients were treated with corticosteroids according to the local protocol of three CIDP expertise centres. Corticosteroid regimens consisted of daily oral prednisolone, pulsed oral dexamethasone, or pulsed intravenous methylprednisolone. Outcomes were number of responders to treatment, remission rate of treatment responders, overall probability of 5-year remission, and the occurrence of adverse events. Results: A total of 125 patients were included. Sixty-seven (54%) patients received daily prednisone or prednisolone, 37 (30%) pulsed dexamethasone, and 21 (17%) pulsed intravenous methylprednisolone. Overall, 60% (95% CI 51–69%) responded to corticosteroids, with no significant difference between the three treatment regimens (p = 0.56). From the 75 responders, 61% (95% CI 50–73%) remained in remission, during a median follow-up of 55 months (range 1–197 months). The probability of responders reaching 5-year remission was 55% (95% Cl 44–70%), with no difference between the three groups. Adverse events leading to a change in treatment occurred in ten patients (8%). Two patients had a serious adverse event. Conclusion: Corticosteroids lead to improvement in 60% of patients and to remission in 61% of treatment responders. There were no differences between treatment modalities in terms of efficacy and safety.
Databáze: OpenAIRE
Externí odkaz: